Compare PCRX & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | ETW |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.0M | 1.0B |
| IPO Year | 2010 | 2005 |
| Metric | PCRX | ETW |
|---|---|---|
| Price | $25.17 | $9.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | ★ 450.1K | 262.4K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $364.29 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $8.46 |
| 52 Week High | $27.64 | $9.64 |
| Indicator | PCRX | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 60.53 | 60.72 |
| Support Level | $22.03 | $9.12 |
| Resistance Level | $27.03 | N/A |
| Average True Range (ATR) | 0.94 | 0.10 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 69.42 | 91.03 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.